Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension
- 5 November 2009
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 361 (19) , 1864-1871
- https://doi.org/10.1056/nejmct0904473
Abstract
A 46-year-old-woman presents with exertional dyspnea and syncope and receives a diagnosis of idiopathic pulmonary arterial hypertension. Treatment with sildenafil is recommended. Sildenafil and tadalafil are phosphodiesterase type 5 inhibitors that ameliorate pulmonary arterial hypertension by increasing levels of cyclic guanosine monophosphate in the smooth-muscle cells of the pulmonary artery.This publication has 41 references indexed in Scilit:
- CorrectionCirculation, 2009
- Tadalafil Therapy for Pulmonary Arterial HypertensionCirculation, 2009
- Pulmonary Vascular Disease in the Developing WorldCirculation, 2008
- Phosphodiesterase 1 Upregulation in Pulmonary Arterial HypertensionCirculation, 2007
- An epidemiological study of pulmonary arterial hypertensionEuropean Respiratory Journal, 2007
- Spatio-Temporal Diversity of Apoptosis Within the Vascular Wall in Pulmonary Arterial HypertensionCirculation Research, 2006
- Efficacy and Safety of Sildenafil Added to Treprostinil in Pulmonary HypertensionThe American Journal of Cardiology, 2005
- Endothelial Dysfunction in Pulmonary HypertensionCirculation, 2004
- Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?International Journal of Cardiology, 2002
- Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial HypertensionCirculation, 2002